New aspects of allergic rhinitis treatment

• Main Authors: Sergei A. Karpishchenko, Olga M. Kolesnikova
• Format: Article
• Language: Russian
• Published: ZAO "Consilium Medicum" 2019-03-01
• Series: Consilium Medicum
• Subjects: allergic rhinitis; antihistamines; ebastine; standards
• Online Access: http://consilium.orscience.ru/en/archive/2019/vol-21-3-2019/new-aspects-of-allergic-rhinitis-treatment_5513/?element
• ISSN: 2075-1753; 2542-2170

Allergic rhinitis is a worldwide disease, which occurred from 17% to 40% of the population in different countries. Allergic rhinitis affects negative on the quality of patient’s life and is often associated with asthma. Modern strategy for the treatment of allergic rhinitis based on three principles: the elimination of contact with the allergic agent, pharmacotherapy and immunotherapy. The second generation of the antihistamines drugs, as a representative of pharmacotherapy, are used at all stages of the allergic rhinitis treatment due to their high therapeutic efficacy and have not only anti-allergic, but also anti-inflammatory effect. In this article provides a comparative review of the effectiveness of second-generation antihistamines drugs among themselves and in comparison with antileukotriene medications. Although the availability of effective drugs for allergic rhinitis treatment, there is some kind of patients who had no effect from drugs. At the recent time, there are some searches for a new drugs and / or delivery methods for “known” drugs that would improve allergic rhinitis treatment. At first sight, intranasal using of drugs combines a good safety with high efficiency. However, after determining the molecular goal, one drug can affect a greater number of diseases or symptoms. From this point of view, it is preferable to use one systemic drug for stopping the variations of an allergic reaction.